{"name":"AIM Vaccine Co., Ltd.","slug":"aim-vaccine-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"SARS-CoV-2 variant mRNA vaccine low dose","genericName":"SARS-CoV-2 variant mRNA vaccine low dose","slug":"sars-cov-2-variant-mrna-vaccine-low-dose","indication":"Other","status":"phase_1"},{"name":"LVRNA009","genericName":"LVRNA009","slug":"lvrna009","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"SARS-CoV-2 variant mRNA vaccine low dose","genericName":"SARS-CoV-2 variant mRNA vaccine low dose","slug":"sars-cov-2-variant-mrna-vaccine-low-dose","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"LVRNA009","genericName":"LVRNA009","slug":"lvrna009","phase":"phase_3","mechanism":"LVRNA009 is an mRNA vaccine designed to stimulate immune responses against specific disease targets through encoded antigen expression.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-31","type":"pipeline","source":"simplywall.st","summary":"AIM Vaccine (SEHK:6660) Losses Persist In H1 FY 2025 Challenging Bullish Growth Narratives - simplywall.st","headline":"AIM Vaccine (SEHK:6660) Losses Persist In H1 FY 2025 Challenging Bullish Growth Narratives","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxPcldGYVBGckR6WWRkZ3BBS2dhZHo5TDc1MDYwZlZnWUZXMnZnbGliWGdvcEVtUVAwUENKUDh6OHNSYVZfd2V1N3pLQmpEaHR5dGctd2Vvd3poZFFmcGQ1WWpJREZHd0Z2WFB0X19xUnRXa2c3eERfMkZoVm9UMVQwczFkOGFhaXVWNDlmZVdzODN2dTJvOS1IZ09RMnNab1lsUmZNWV95YkFBSy14OTQtY25vMmtZbFNqcW9QUHJIY0xHcHlsQmFKWg?oc=5","date":"2026-02-13","type":"pipeline","source":"Proactive Investors","summary":"SMALL-CAP MOVERS: Difficult week for two of AIM's minnows | AIM:PXC, OTCQX:PXCLF - Proactive Investors","headline":"SMALL-CAP MOVERS: Difficult week for two of AIM's minnows | AIM:PXC, OTCQX:PXCLF","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPV1E1NGhLYThrek5CNXlLbWd1YkctSnBuYUJUTll3a1FyVVozenJicVd4SjMwcUFjb20wV3RuMnZiREZfQk1aVlUxQUlVYWNuN3RwNVE5dHFmc3o1bGRMY09RTUxKUkhzVFRJUVNITG1xX2txWDlEcGJxM1NocTV5eW9hZkpHY0RSWUlyS01aMmdMTU9INzI1MnpYN1p0RFZHNXlhVEo0N29KXzBkNDhCWXBZNEluZ2g0amZV?oc=5","date":"2026-02-03","type":"pipeline","source":"reuters.com","summary":"Buoyed by Kennedy's success, MAHA groups take aim at state vaccine laws - reuters.com","headline":"Buoyed by Kennedy's success, MAHA groups take aim at state vaccine laws","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxQUkVYVkFZYjBuSXNxNHRVbFBETnpORWVuQnZYQ3BVV2ZYSWxEWU1zOUxaVkQxZXFvTjV6NjdrZWE2QjBnblZTdmh5RlZlVHlxeW5uZGdCWHlBcEJ2Z0VWeVF4SlZ0V0RTQVJKdnVnMzFaeFZ2TktRRl9xSmJ4RDk0bUhjU09odnBaTVlzR3RySjRCQ0hvLXltM0Q0QWthVldQLUw3RVlNVU9nZHpLdXM0bDFzSnRXNXItcVZfVXJTbkh5dUNtS3hPbGpFbw?oc=5","date":"2025-10-07","type":"pipeline","source":"LinkedIn","summary":"Global pharmaceutical giant Eli Lilly and Company has announced a ₹9,000 crore investment to establish a large-scale manufacturing and quality hub in Hyderabad. The decision follows a meeting between ","headline":"Global pharmaceutical giant Eli Lilly and Company has announced a ₹9,000 crore investment to establish a large-scale man","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxNSHlDV2RyTXVnNTFyWk01SVJKdGxkSWRrQnZfTkFHb050cHZjdWF5d3JCZmRCd3NXRmFyWUNXa1Atc3BhZk5ZNmhfWlBGWEU1MkdTbUFTVmt4Q19KUnp5MXhBeVR1aDFaNGgydEZBS1JCRTgtVFZDMFJyeVlrR1RtQ0VFUVJZTFRlMC1mb1BXQV9NRVJfZnp6Yjllc25QUUJ4M3pXZkY2SnMwMEcxU0VEcGozTzlnS2s?oc=5","date":"2025-09-23","type":"deal","source":"Share Talk","summary":"N4 Pharma plc (AIM: N4P) Partnership with University of Strathclyde's CMAC National Facility - Share Talk","headline":"N4 Pharma plc (AIM: N4P) Partnership with University of Strathclyde's CMAC National Facility","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-17","type":"regulatory","source":"PBS","summary":"FDA takes aim at telehealth companies for promoting unofficial weight loss drug dupes - PBS","headline":"FDA takes aim at telehealth companies for promoting unofficial weight loss drug dupes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAJBVV95cUxQV3p0WXY5ZXdmOG1nQ0hYMFQyVWs2SDhvWjZYNm1XOGRBLXNPdzEtWGo5WTJvSVVRVi1icS05U1hQcUhGRGxGQWxxdF9qejJuWm1BYlRJT2dYaEVmTzkyclRQWllNSmVMSEZheW9TREtoQ05vTzUxQkdSSXE2UFFJOXNHSkNIU0RhU0szNVVTX1FIRU4zU1RLeWh6Q2d1LVZqRmIxNlJUZWFvSWplYWlWTjJoTW5DdnFYXy1Zc01QQzNiZmxSWVRjWU1ZQnFieE1sbDFwZG9JVGhOOVhZelpWM0ZMMXluU2VrdDBEVDliV0RyRmhZblVDREpvVkRhWGdhZTROUWZFaVlhM3FOWWJuRDZXemRkd21Tc2RDOEsxR3BHcW1saEItV1ZvUkxDendudDZBZHFwUlNCRzc2NVBCYmdrMzc?oc=5","date":"2025-08-28","type":"trial","source":"globenewswire.com","summary":"Antisense Oligonucleotide Therapeutics Clinical Trial - globenewswire.com","headline":"Antisense Oligonucleotide Therapeutics Clinical Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AJBVV95cUxPN202TUJ4Nm1xZ3AwUEFZbjh0cGl1NWc5WDJFLW03VHhlZnV0R28wOFR4UC0wNlJnSHV6WVY4aG9mdEtDZ1phbHdKWnUyaEhuTzUteERfdkpJdnA1S1VZVGp3TlpwcXhxeEJZeEttTzYwZlNKTHBtZ0dXVGhtSnZZeUs3bkxhTFpVZ2d0c3d5Mm83eGtlRmZJU3FseW5lYVhoeVBESV8zRW9fb1FPTk1jd1ZUb1dyeGlrTFBuMUhCcFBzTnI2azJadG9fWHlxVS1RX0Roc3NNbnIwS19aVEJXbE5zQUJBUHVwdDhhYlluVGZhcXlRVW1wak5xazJ2bFlNMmFzaV9oVENvOWRsTEJFdVRwc2Z3TURveTlIRkJRQXpLV3JWTldMRnBwZG1EdEJSVGdTVlhUVktvS3drSHFrTGFZUmhpcnpOUXl2cEN5OERFZVpE?oc=5","date":"2025-06-17","type":"trial","source":"globenewswire.com","summary":"Oligonucleotides Clinical Trial Pipeline Analysis - globenewswire.com","headline":"Oligonucleotides Clinical Trial Pipeline Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQdlMwR2c1OHpZQ2J0aFdHU04tSk5fMEtXREFyU09aOUctN0xUajFhMWZQRmhad2lZaE9tZlJoZm1sOGkySjZYRjc1aGRCT0xVNGtCSjNrb0gxOEJzVC1VUlpVUnVVSUZ6bV9IZ0FLUWRDSVpISFdCX2VGbXZuODRJSE4wdDlXN1B2djVvUVpZYmVJQ0ZKaF94Q3lyTHp2b2lqOFR4SnVaTm1abGN3UlFXNDFYRkJaUQ?oc=5","date":"2025-05-23","type":"pipeline","source":"BioSpace","summary":"‘Make American Healthy Again’ Report Takes Aim at Pharma Lobbying, GLP-1s and Vaccines - BioSpace","headline":"‘Make American Healthy Again’ Report Takes Aim at Pharma Lobbying, GLP-1s and Vaccines","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-05-22","type":"pipeline","source":"The Times of India","summary":"RFK Jr.'s MAHA report takes aim at vaccines, American diet, and pharma practices - The Times of India","headline":"RFK Jr.'s MAHA report takes aim at vaccines, American diet, and pharma practices","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxPZ09PRU1jSjg3c0ExVFVhNFRhS0lVY2IwNnNaUklvYkJhLWpjSk9zWVMwSVJuT0dxUzN4ZHdTQmVzMjgyUGNNVzZlMnkxRzAtN3pDc2lLWkp5LWt5SV9MME54TGJncUVoMUpWQjFPZG8tNHJFMmt0aXRFTlpGVFFZU1h5d0RwTnVMd1h6TEYxZ1AtUDB4UXNuaTV6Nk1SRkVQNGM5NG5hOVlEUVB3aExUaUhlOWk5Y2JHRnExLWYzVGlWeWlZdXp1ajdwYm92ZzVCY3AwSklZdDlLN1VTQnNqcQ?oc=5","date":"2025-04-03","type":"regulatory","source":"BioPharma APAC","summary":"China’s AIM Vaccine Set to Launch World’s First Serum-Free Rabies Vaccine Following Regulatory Acceptance - BioPharma APAC","headline":"China’s AIM Vaccine Set to Launch World’s First Serum-Free Rabies Vaccine Following Regulatory Acceptance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNNTZ3VGFtajd1MWhjWDRJSjJpRl9ONFFZVGJKdTVybjN5TDZCdkNueXE2cGhYcjB1RUhoQjNad0NvanlqWFdsNXpqU0ZhWWxfbmVON0ZzVUcwMGVaUkhITzBvRENidTc5Yk9wTmFBdXdoWXR4RGJmd0tEZEY5OVJQbWc2UzFIalotbVpOcnR1bmctQmxMY1NMNUI0UWxydEV5TFE?oc=5","date":"2025-03-18","type":"regulatory","source":"BioWorld News","summary":"Aim seeks approval of first serum-free human rabies vaccine - BioWorld News","headline":"Aim seeks approval of first serum-free human rabies vaccine","sentiment":"positive"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":1,"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}